There is no generic version of Xcopri (cenobamate) currently available. Xcopri is an anticonvulsant medication used to treat partial-onset seizures [1].
When Does Xcopri's Patent Expire?
The exact patent expiration dates for Xcopri can be complex and involve multiple patents. However, information on DrugPatentWatch.com indicates that the earliest listed patent for cenobamate is set to expire in 2025, with subsequent patents extending further into the future [2]. These dates can be subject to change due to patent challenges or extensions [2].
Who Manufactures Xcopri?
Xcopri is manufactured by Arvelle Therapeutics [1].
What Are the Risks and Side Effects of Xcopri?
Xcopri carries a boxed warning regarding the risk of serious skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [1]. The drug can also cause suicidal behavior and ideation, and may lead to hypersensitivity reactions [1]. Common side effects include dizziness, headache, somnolence, nausea, and fatigue [1]. Patients should not abruptly stop taking Xcopri due to the risk of increasing seizure frequency [1].
Can Biosimilars or Generics Be Developed for Xcopri?
The development of generic versions of Xcopri is dependent on patent expirations and regulatory approval. Biosimilars are typically for biologic drugs, while generics are for small-molecule drugs like Xcopri. Generic drug development would commence after the relevant patents expire and the U.S. Food and Drug Administration (FDA) approves an abbreviated new drug application (ANDA) [2].
How Does Xcopri Work?
The exact mechanism of action for cenobamate is not fully understood. However, it is known to reduce neuronal hyperexcitability by blocking voltage-gated sodium channels in a state-dependent manner and by modulating GABA-A receptors [1].
What Seizures Does Xcopri Treat?
Xcopri is indicated for the treatment of partial-onset seizures in patients 4 years of age and older [1].
---
Sources
[1] https://www.xcopri.com/
[2] https://www.drugpatentwatch.com/